Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Circulation study

This article was originally published in The Tan Sheet

Executive Summary

The rates of treatment and control of high cholesterol are "far from optimal," especially among individuals at intermediate and high risk for cardiovascular disease, a study published in the Feb. 7 Circulation finds. Roughly half of the individuals at high- and intermediate-risk of CVD had untreated high cholesterol, or dyslipidemia, compared to less than 20% of individuals in the low-risk group. Additionally, "there is evidence of gender and ethnic disparities in both treatment and control," David Goff, MD/PhD, Wake Forest University School of Medicine, et al., state. "Efforts to improve the treatment and control of dyslipidemia and to eliminate disparities...should be considered among our highest national healthcare quality improvement priorities," they conclude. Goff et al. evaluated 6,704 patients from the Multi-Ethnic Study of Atherosclerosis, a cohort study of individuals between 45-84 years old who were free of clinical CVD at baseline (2000-2002)...

You may also be interested in...

Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts